Diabetes researcher Zimmett honoured
19 September, 2003 by Tanya HollisDiabetes luminary Prof Paul Zimmet has been honoured by his peers, receiving the Kellion Award for his contribution to the field.
pSivida claims success in anti-tumour device study
19 September, 2003 by Tanya HollisA nano-structured silicon device containing slow-release radiotherapy has successfully halted tumours in an animal study.
Peplin spruiks promising new compound
16 September, 2003 by Graeme O'NeillBrisbane's Peplin Biotech Ltd (ASX:PEP) has had a good week, reporting a promising new indication for its lead anti-cancer compound PEP005, and promising activity from a new compound of undisclosed provenance.
Monash researchers claim key MS find
15 September, 2003 by Graeme O'NeillMonash University researchers have solved the crystal structure of the protein suspected to be the focus of the autoimmune attack that destroys the fatty insulating sheath around neurons in the brain in multiple sclerosis (MS).
Solbec claims cancer success with plant extract
08 September, 2003 by Graeme O'NeillWestern Australian biotech company Solbec Pharmaceuticals (ASX:SBP) may have struck therapeutic gold in a thorny wayside weed called devil's apple (Solanum linnaeanum) .
Bionomics upbeat despite bigger annual loss
05 September, 2003 by Graeme O'NeillAdelaide epilepsy specialist Bionomics (ASX:BNO) has reported an after-tax loss of $4.54 million for the year to June 30, up from $3.49 million in 2001-02.
Monash launches new brain research centre
05 September, 2003 by Melissa TrudingerMonash University yesterday launched its new Centre for Brain and Behaviour, bringing together more than 150 researchers including students and postdocs from 21 university departments and research centres.
Eiffel signs US insulin trial deal
05 September, 2003 by Graeme O'NeillMelbourne drug re-engineering company Eiffel Technologies (ASX:EIF) has signed an agreement with a large US drug-delivery company to trial an inhalable form of insulin produced by Eiffel's proprietary supercritical fluid technology.
Arthritis CRC picks up new funding and partners
03 September, 2003 by Melissa TrudingerThe Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs.
AustCancer finds cancer jammer molecule
02 September, 2003 by Graeme O'NeillPerth-based cancer therapeutics developer Australian Cancer Technology's (ASX:ACU) joint discovery project with Cambridge-based BioFocus (AIM:BIO) has designed a tiny spanner to jam the molecular works of cancer cells that evade conventional chemotherapy and radiotherapy.
Hunt for SARS source far from over: researcher
02 September, 2003 by Graeme O'NeillVirologists have some suspects, but the animal that originally hosted the lethal coronavirus that causes severe acute respiratory syndrome (SARS) in humans remains unidentified.
Qld's Élan joins with US Meditech on biohazard
01 September, 2003 by Melissa TrudingerQueensland company Élan BioDynamics, a wholly owned subsidiary of the Élan Group, has entered a joint venture with US company Meditech Pharmaceuticals to commercialise a system for detection of biological hazards including aflatoxin, and anthrax.
New virus linked to breast cancer
22 August, 2003 by Jeremy TorrResearchers at the Prince of Wales Hospital have established a link between breast cancer and the human form of a mouse virus.
Novogen scores new US patent
19 August, 2003 by Jeremy TorrBiopharma Novogen has been granted a US patent for isoflavone treatment for fibroids and endometriosis specific to women.
Victor Chang Institute to work with BioDiem
19 August, 2003 by Jeremy TorrSydney's Victor Chang Cardiac Research Institute has signed a deal to investigate a tissue restorative agent, BDM-K, for Melbourne biopharma BioDiem
